Single nucleotide polymorphisms located in 5' untranslated regions (5'UTRs) can regulate gene expression and have clinical impact. Recognition of functionally significant sequences within 5'UTRs is crucial in next-generation sequencing applications. Furthermore, information about the behavior of 5'UTRs during gene evolution is scarce. Using the example of the ATP-binding cassette transporter A1 (
- MeSH
- 5' nepřekládaná oblast * genetika MeSH
- ABCA1 protein chemie genetika MeSH
- anotace sekvence MeSH
- fylogeneze MeSH
- introny MeSH
- konformace nukleové kyseliny MeSH
- konzervovaná sekvence genetika MeSH
- lidé MeSH
- messenger RNA genetika metabolismus MeSH
- nukleotidové motivy genetika MeSH
- otevřené čtecí rámce genetika MeSH
- savci genetika MeSH
- sekvence aminokyselin MeSH
- sekvence nukleotidů MeSH
- sestřih RNA genetika MeSH
- zastoupení bazí genetika MeSH
- zesilovače transkripce genetika MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- MeSH
- ABC transportéry genetika izolace a purifikace metabolismus MeSH
- ABCA1 protein genetika izolace a purifikace metabolismus MeSH
- experimenty na zvířatech MeSH
- financování organizované MeSH
- hypolipidemika metabolismus MeSH
- krysa rodu rattus MeSH
- messenger RNA izolace a purifikace metabolismus účinky léků MeSH
- nenasycené mastné kyseliny metabolismus MeSH
- omega-3 mastné kyseliny * metabolismus terapeutické užití MeSH
- silymarin * metabolismus terapeutické užití MeSH
- statistika jako téma MeSH
- transportní proteiny * izolace a purifikace metabolismus účinky léků MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
AIMS: The effects of cholesteryl ester transfer protein (CETP) inhibition on lipids, inflammation, and markers of high-density lipoprotein (HDL) function, following an acute coronary syndrome (ACS), are unknown. METHODS AND RESULTS: The dal-ACUTE study randomized 300 patients (1 : 1) to dalcetrapib 600 mg/day or placebo within 1 week of an ACS. The primary endpoint was per cent change in HDL-cholesterol (HDL-C) after 4 weeks. Secondary endpoints included apolipoprotein levels, markers of HDL function, and inflammation. Dalcetrapib treatment increased HDL-C and apolipoprotein A1 by 33.7 and 11.8%, respectively (both P < 0.001) and total cholesterol efflux by 9.5% (P = 0.003) after 4 weeks, principally via an increase in non-ATP-binding cassette transporter (ABC) A1-mediated efflux, without statistically significant changes in pre-β1-HDL levels. The increase in total efflux with dalcetrapib correlated most strongly with increases in apolipoprotein A1 and HDL-C (r = 0.46 and 0.43, respectively) rather than the increase in pre-β1-HDL (r = 0.32). Baseline and on-treatment ABCA1-mediated efflux correlated most strongly with pre-β1-HDL levels; in contrast, non-ABCA1-mediated efflux correlated better with apolipoprotein A1 and HDL-C levels. CONCLUSIONS: High-density lipoprotein raised through CETP inhibition with dalcetrapib improves cholesterol efflux, principally via a non-ABCA1-mediated pathway. While HDL-C was increased by one-third, apolipoprotein A1 and total efflux were increased only by one-tenth, supporting the concept of dissociation between improvements in HDL function and HDL-C levels, which may be of relevance to ongoing trials and the development of therapeutic interventions targeting HDL.
- MeSH
- ABCA1 protein metabolismus MeSH
- akutní koronární syndrom farmakoterapie MeSH
- anticholesteremika aplikace a dávkování MeSH
- apolipoproteiny metabolismus MeSH
- biologické markery metabolismus MeSH
- C-reaktivní protein metabolismus MeSH
- dvojitá slepá metoda MeSH
- HDL-cholesterol metabolismus MeSH
- infarkt myokardu farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipoproteiny metabolismus MeSH
- metabolismus lipidů účinky léků MeSH
- nestabilní angina pectoris farmakoterapie MeSH
- rozvrh dávkování léků MeSH
- sulfhydrylové sloučeniny aplikace a dávkování MeSH
- transportní proteiny pro estery cholesterolu antagonisté a inhibitory MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
α-Tocopheryl succinate (α-TOS) is a promising anti-cancer agent due to its selectivity for cancer cells. It is important to understand whether long-term exposure of tumour cells to the agent will render them resistant to the treatment. Exposure of the non-small cell lung carcinoma H1299 cells to escalating doses of α-TOS made them resistant to the agent due to the upregulation of the ABCA1 protein, which caused its efflux. Full susceptibility of the cells to α-TOS was restored by knocking down the ABCA1 protein. Similar resistance including ABCA1 gene upregulation was observed in the A549 lung cancer cells exposed to α-TOS. The resistance of the cells to α-TOS was overcome by its mitochondrially targeted analogue, MitoVES, that is taken up on the basis of the membrane potential, bypassing the enhanced expression of the ABCA1 protein. The in vitro results were replicated in mouse models of tumours derived from parental and resistant H1299 cells. We conclude that long-term exposure of cancer cells to α-TOS causes their resistance to the drug, which can be overcome by its mitochondrially targeted counterpart. This finding should be taken into consideration when planning clinical trials with vitamin E analogues.
- MeSH
- ABC transportéry genetika fyziologie MeSH
- ABCA1 protein MeSH
- alfa-tokoferol terapeutické užití MeSH
- chemorezistence * MeSH
- genový knockdown MeSH
- mitochondrie účinky léků MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádory plic farmakoterapie MeSH
- nemalobuněčný karcinom plic farmakoterapie MeSH
- protinádorové látky farmakologie MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH